Clinical Trial Update: Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT) [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing Perforomist to Foradil in COPD patients, evaluated by inspiratory capacity and high-resolution CT, has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchitis
• Chronic Obstructive Pulmonary Disease
• Emphysema

Drugs mentioned

• Foradil (formoterol)
• Perforomist (formoterol fumarate)

Snippet

Sponsor: University of California, Los Angeles | Conditions: Chronic Obstructive Pulmonary Disease, COPD | Phase 4 | Status: WITHDRAWN